Island Pharmaceuticals Expands Pipeline with Acquisition of Antiviral Program
Island Pharmaceuticals, an Australian company developing antiviral drugs for unmet medical needs, has acquired the Galidesivir antiviral program from BioCryst Pharmaceuticals Inc. This acquisition, finalized through an asset purchase agreement, accelerates an earlier option agreement following positive due diligence. Island’s lead candidate, ISLA-101, is a repurposed drug with a strong safety profile, currently in development for the prevention and treatment of dengue fever and other mosquito-borne diseases. Galidesivir, a broad-spectrum antiviral with U.S. government-backed R&D, will now be advanced by Island with a focus on treating Marburg virus. The company plans to pursue FDA approval under the Animal Rule pathway, which may allow for regulatory submission based on animal efficacy data, potentially requiring just one more successful animal study before filing a New Drug Application.
Island Pharmaceuticals Expands Pipeline with Acquisition of Antiviral Program